Fig. 3From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final resultsInvestigator-assessed duration of response in responders, intent-to-treat population (Cohort 1). The tick marks indicate censoring eventsBack to article page